Match tier Confirmed
Presence Current · Arkansas
Last published 2026
Sources OpenAlex · ORCID
Refreshed 2026-10-09

Ruud P.M. Dings

Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.

Federal Grant PI High Impact

Associate Professor

Also affiliated: University of Minnesota (2002–2024); University of Arkansas Medical Center (2021–2026); Maastricht University Medical Centre (2003–2011); Maastricht University (2003–2011); Masonic Cancer Center (2011)

40 h-index 130 pubs 5,312 cited

  • Animals
  • Mice
  • Humans
  • Angiogenesis Inhibitors
  • Female
  • Peptides
  • Neovascularization, Pathologic
  • Cell Line, Tumor
  • Antineoplastic Agents
  • Neoplasms
  • Proteins
  • Mice, Nude
  • Endothelial Cells
  • Combined Modality Therapy
  • Xenograft Model Antitumor Assays

Biography and Research Information

OverviewAI-generated summary

Ruud P.M. Dings' research focuses on cancer biology and treatment, with a particular emphasis on angiogenesis and its role in tumor growth. His work investigates how targeting tumor vasculature can be a therapeutic strategy. This includes studying specific inhibitors like Galectin-1 and examining the effects of combining anti-angiogenesis therapies with other treatments, such as radiation and metformin.

Dings has received funding from the NIH/National Cancer Institute for research aimed at improving cellular immunotherapy during dysbiosis. His publications also explore the molecular mechanisms underlying tumor angiogenesis, including the epigenetic regulation of endothelial cell anergy and the targeting of specific angiogenic vasculature in colon cancer. He has also investigated the potential of novel antitumor agents, such as calixarene 0118, as inhibitors of galectin-1.

With a career marked by significant scholarly output, Dings has an h-index of 40 and has authored over 128 publications, accumulating more than 5,307 citations. He actively collaborates with researchers at the University of Arkansas for Medical Sciences and the University of Arkansas at Fayetteville, including Samir V. Jenkins and Robert Griffin.

Metrics

  • h-index: 40
  • Publications: 130
  • Citations: 5,312

Positions

  • Associate Professor 2022–present
    University of Arkansas for Medical Sciences Radiation Oncology ORCID

Selected Publications

  • Synthesis of Peptide Analogs From Fish Venom With Potential Antimicrobial and Anticancer Activity (2026)
    Chemical Biology & Drug Design DOI OpenAlex
  • Abstract 4785: Thermal regulation of dysbiotic tumor vasculature (2026)
    Cancer Research DOI OpenAlex
  • Abstract 7625: Development of a blood-based tumor hypoxia detection assay (2026)
    Cancer Research DOI OpenAlex
  • Modified tumor uptake and biodistribution of nanoparticles coated with small extracellular vesicle membranes derived from distinct tumor cell lines (2026)
    International Journal of Hyperthermia DOI OpenAlex
  • Investigating Biomarkers of Radiation Resistance in Head and Neck Cancer Using Raman Spectroscopy (2025)
  • CB-839 induces reversible dormancy in lung tumor-cells (2024)
    European Journal of Pharmacology 8 citations DOI OpenAlex
  • Bystander Effects in Spatially Fractionated Radiation Therapy: From Molecule To Organism To Clinical Implications (2024)
    Seminars in Radiation Oncology 18 citations DOI OpenAlex
  • Morphological Effects and In Vitro Biological Mechanisms of Radiation-Induced Cell Killing by Gold Nanomaterials (2023)
    ACS Applied Materials & Interfaces 3 citations DOI OpenAlex
  • Supplemental Figures 1-9 and Table S1 from Gastrointestinal Tract Dysbiosis Enhances Distal Tumor Progression through Suppression of Leukocyte Trafficking (2023)
  • Supplemental Figures 1-9 and Table S1 from Gastrointestinal Tract Dysbiosis Enhances Distal Tumor Progression through Suppression of Leukocyte Trafficking (2023)
  • Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy (2022)
    Angiogenesis 55 citations DOI OpenAlex
  • Abstract 3529: T-cell trafficking and extravasation is suppressed in distal tumors during gastrointestinal tract dysbiosis (2022)
    Cancer Research DOI OpenAlex
  • Gold nanorods enhance different immune cells and allow for efficient targeting of CD4+ Foxp3+ Tregulatory cells (2021)
    PLoS ONE 5 citations DOI OpenAlex
  • Nanoscale investigation and control of photothermal action of gold nanostructure-coated surfaces (2021)
    Journal of Materials Science 7 citations DOI OpenAlex
  • Dysbiotic stress increases the sensitivity of the tumor vasculature to radiotherapy and c-Met inhibitors (2021)
    Angiogenesis 4 citations DOI OpenAlex

View all publications on OpenAlex →

Federal Grants 1 $348,182 total

NIH Contact PI Sep 2021 - Aug 2027

Improvement of cellular immunotherapy during dysbiosis- Resubmission

National Cancer Institute $348,182 R01

Collaboration Network

149 Collaborators 67 Institutions 13 Countries

Top Collaborators

View profile →
View profile →
View profile →
View profile →
View profile →
View profile →

Similar Researchers

Based on overlapping research topics